Pedrosa MR, Franco DR, Gieremek HW, Vidal CM, Bronzeri F, de Cassia Rocha A, de Carvalho Cara LG, Fogo SL, Eliaschewitz FG (2022) GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Tirzepatide achieved previously unheard-of results for a single agent in the SURPASS clinical trial program, lowering body weight by 5.411.7 kg and HbA1c by 1.24-2.58 percentage points
Cohn 5 , Henriette Farkas 6 , Henry Li 7 , James Hao 8 , Michael Smith8, Paolo Bajcic 8 , Paul Audhya 8 , Markus Magerl 9,10 1 AARA Research Center, Dallas, TX, USA
Treatments that work for age-related facial volume loss, including biostimulators and RF microneedling, work equally well for GLP-1-related volume loss
We can discover the best Mounjaro claimants for you according to your specific eligibility requirements.